NTRA
Natera, Inc.
$276.27
+4.82 (+1.78%)
At close · Jul 1
Insider flow:
Net -$38.1M over 90 days · 100% sells
Short interest:
3.01% of float · ▲ +19.4% MoM · 4.0 days cover
1 Up Day
Indicators
Price
Panels
Event markers
Price & Indicators
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$276.27
Open$273.00
Day$266.33–279.42
52W$131.81–279.42
Avg vol 30d1.5M
Short int4.3M · 4.0d
Short vol39%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 8
Equibles Rating
blended score
Overall
Buy
Technical · trend & momentum
Buy
+
Price vs 200-day avg · +32% above
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+32% above
+
Price vs 50-day avg
+28% above
−
RSI (14)
77 · overbought
+
MACD trend
positive
+
52-week position
98% · near high
Sentiment · smart money
Neutral
+
Institutional flow · 1 of 761 funds reported for Jun 30 · net +4.1K sh shares
◦
Trend (MA cross)
50d $216 › 200d $210 — 50d above 200d
+
Institutional flow
1 of 761 funds reported for Jun 30 · net +4.1K sh shares
−
Insider flow
Net -$38.1M over 90 days · 100% sells
−
Short interest
3.01% of float · ▲ +19.4% MoM · 4.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
761 holders — near 3-yr high, broad support
Fundamentals
Strong
+
Free cash flow · $109.1M
−
Revenue growth
−3% Y/Y
◦
EPS growth
+1% Y/Y
+
Free cash flow
$109.1M
+
Balance sheet
net cash $183.1M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Key facts
Market Cap
$39.57B
Shares
143,215,382
CIK
1604821
CUSIP
632307104
13F Activity (30d)
8 filings
5 filers
Website
Visit website
Investor Relations
Investor relations
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Total revenue
· 2026
$2.74B – $2.82B
prior FY $2.31B
midpoint +20.5% Y/Y
Gross margin
· 2026
64% – 66%
Selling, general and administrative costs
· 2026
$1.13B – $1.23B
Research and development costs
· 2026
$800M – $900M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+32% above
Bullish
Price vs 50-day avg
+28% above
Bullish
RSI (14)
77 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
98% · near high
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $216 › 200d $210 — 50d above 200d
Institutional flow
Accumulating
1 of 761 funds reported for Jun 30 · net +4.1K sh shares
Insider flow
Distributing
Net -$38.1M over 90 days · 100% sells
Short interest
Rising
3.01% of float · ▲ +19.4% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
761 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $132
Now $276 · 98%
52-wk high $279
vs 200-day avg +32%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases and calls| Metric | Latest | Period | YoY |
|---|---|---|---|
| Oncology tests processed | 258,900 | Q1 2026 | — |
| Tests accessioned | 999,200 | Q1 2026 | — |
| Tests processed | 1,013,600 | Q1 2026 | — |
| Tests reported in our laboratory | 918,100 | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NTRA
this stock
Natera, Inc.
|
$39.57B | +20.6% | -2.8% | — | 3.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$190.76B | -11.3% | +0.4% | 28.2 | 1.2% |
|
DHR
Danaher Corp /De/
|
$134.82B | -16.6% | +8.5% | 36.8 | 1.6% |
|
IDXX
Idexx Laboratories Inc /De
|
$42.41B | -20.5% | +10.4% | 39.6 | 2.7% |
|
A
Agilent Technologies, Inc.
|
$37.52B | -2.0% | +6.4% | 26.7 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NTRA | +6.3% | +29.9% | +8.6% | +1.8% | +20.6% |
| SPY | +1.7% | -1.8% | +8.2% | -0.1% | +9.4% |
| vs SPY | +4.6% | +31.7% | +0.5% | +1.9% | +11.2% |